Literature DB >> 21891820

Smad molecules expression pattern in human bronchial airway induced by sulfur mustard.

Maryam Adelipour1, Abbas Ali Imani Fooladi, Samaneh Yazdani, Ensieh Vahedi, Mostafa Ghanei, Mohammad Reza Nourani.   

Abstract

Airway remodelling is characterized by the thickening and reorganization of the airways seen in mustard lung patients. Mustard lung is the general description for the chronic obstructive pulmonary disease induced by sulfur mustard(SM). Pulmonary disease was diagnosed as the most important disorder in individuals that had been exposed to sulfur mustard. Sulfur mustard is a chemical warfare agent developed during Wars. Iraqi forces frequently used it against Iranian during Iran -Iraq in the 1980-1988. Peribronchial fibrosis result from airway remodeling that include excess of collagen of extracellular matrix deposition in the airway wall. Some of Smads families in association with TGF-β are involved in airway remodeling due to lung fibrosis. In the present study we compared the mRNA expression of Smad2, Smad3, and Smad4 and Smad7 genes in airway wall biopsies of chemical-injured patients with non-injured patients as control. We used airway wall biopsies of ten unexposed patients and fifteen SM-induced patients. Smads expression was evaluated by RT-PCR followed by bands densitometry. Expression levels of Smad3 and Smad4 in SM exposed patients were upregulated but Smad2 and Smad7 was not significantly altered. Our results revealed that Smad3, and 4 may be involved in airway remodeling process in SM induced patients by activation of TGF-β. Smad pathway is the most represented signaling mechanism for airway remodeling and peribronchial fibrosis. The complex of Smads in the nucleus affects a series of genes that results in peribronchial fibrosis in SM-induced patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21891820     DOI: 010.03/ijaai.147154

Source DB:  PubMed          Journal:  Iran J Allergy Asthma Immunol        ISSN: 1735-1502            Impact factor:   1.464


  7 in total

1.  Inhalation of sulfur mustard causes long-term T cell-dependent inflammation: possible role of Th17 cells in chronic lung pathology.

Authors:  Neerad C Mishra; Jules Rir-sima-ah; Gary R Grotendorst; Raymond J Langley; Shashi P Singh; Sravanthi Gundavarapu; Waylon M Weber; Juan C Pena-Philippides; Matthew R Duncan; Mohan L Sopori
Journal:  Int Immunopharmacol       Date:  2012-03-28       Impact factor: 4.932

Review 2.  Mustard vesicant-induced lung injury: Advances in therapy.

Authors:  Barry Weinberger; Rama Malaviya; Vasanthi R Sunil; Alessandro Venosa; Diane E Heck; Jeffrey D Laskin; Debra L Laskin
Journal:  Toxicol Appl Pharmacol       Date:  2016-05-19       Impact factor: 4.219

3.  Treatment for sulfur mustard lung injuries; new therapeutic approaches from acute to chronic phase.

Authors:  Zohreh Poursaleh; Ali Amini Harandi; Ensieh Vahedi; Mostafa Ghanei
Journal:  Daru       Date:  2012-09-10       Impact factor: 3.117

4.  Perspective in future pharmacological approach to sulfur mustard lung injuries.

Authors:  Amin Saburi; Majid Shohrati; Mostafa Ghanei
Journal:  J Res Med Sci       Date:  2012-11       Impact factor: 1.852

5.  Evaluation of miR-9 and miR-143 expression in urine specimens of sulfur mustard exposed patients.

Authors:  Mostafa Khafaei; Shahram Samie; Seyed Javad Mowla; Akbar Ghorbani Alvanegh; Behnaz Mirzaei; Somaye Chavoshei; Ghamar Soltan Dorraj; Mostafa Esmailnejad; Mahmood Tavallaie; Mohammadreza Nourani
Journal:  Interdiscip Toxicol       Date:  2015-12

6.  Pathway reconstruction of airway remodeling in chronic lung diseases: a systems biology approach.

Authors:  Ali Najafi; Ali Masoudi-Nejad; Mostafa Ghanei; Mohamad-Reza Nourani; Ali Moeini
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

Review 7.  Epigenetic: A missing paradigm in cellular and molecular pathways of sulfur mustard lung: a prospective and comparative study.

Authors:  Saber Imani; Yunes Panahi; Jafar Salimian; Junjiang Fu; Mostafa Ghanei
Journal:  Iran J Basic Med Sci       Date:  2015-08       Impact factor: 2.699

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.